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Aim: Growing evidence shows a strong interplay between post-transcriptional regulation, mediated
by miRNAs (miRs) and epigenetic regulation. Nevertheless, the number of experimentally validated miRs
(called epi-miRs) involved in these regulatory circuitries is still very small.Material & methods:We propose
a pipeline to prioritize candidate epi-miRs and to identify potential epigenetic interactors of any given
miR starting frommiR transfection experiment datasets. Results & conclusion:We identified 34 candidate
epi-miRs: 19 of them are known epi-miRs, while 15 are new. Moreover, using an in-house generated gene
expression dataset, we experimentally proved that a component of the polycomb-repressive complex 2,
the histone methyltransferase enhancer of zeste homolog 2 (EZH2), interacts with miR-214, a well-known
prometastatic miR in melanoma and breast cancer, highlighting a miR-214-EZH2 regulatory axis poten-
tially relevant in tumor progression.
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miRNAs (miRs) are small noncoding RNAs that negatively regulate gene expression in metazoans and plants [1,2].
They are relevant in physiological processes ranging from development and metabolism to apoptosis and signaling
pathways [3,4]. Moreover, their expression is altered in several human diseases, particularly in cancer [5,6], making
miRs a major focus of research in molecular biology.
In the last few years, the interplay between miRs and the epigenetic layers of regulation has been intensely
investigated. A growing amount of evidence supports the importance of a few selected miRs in regulating epigenetic
factors [7]. At the same time, several miRs (and among them most of the known epi-miRs) have been shown to be
under strict epigenetic control [7–11]. This interplay is so deep that it has been recently suggested that epigenetic
regulation could be only understood considering epigenetic regulators (epi-Rs) and miRs as partners of combined
regulatory circuitries [12]. Four are the main epigenetic pathways involved in this kind of networks and considered
in our analysis. The polycomb-repressive complex 1 (PRC1), a transcriptional-repressor complex consisting of
several proteins among which an important role is played by the Polycomb group ring finger ones (in particular
Bmi-1) and whose action is responsible of the ubiquitylation of H2AK119ub1 [13]. Belonging to the same family
of repressors, the PRC2 is composed of four subunits: RbAp48, SUZ12, the histone methyltransferase EZH2 and
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EED. PRC2 can work alone by adding the repressive mark of trimethylated histone H3 at lysine 27 (H3K27me3)
to its target genes or in cooperation with NIPP1 [14] to increase its repressive action. DNA methyltransferases
(DNMT) involved in DNA methylation have, in general, a transcriptional-repressive role, especially on CpG-rich
promoters [15]; while histone deacetylases (HDACs), involved in histone deacetylation, act mainly as transcriptional
corepressors [16]. In order to simplify the analysis, we made the assumption that these four epigenetic pathways exert
their function mainly as repressors even if, for example, HDACs can also act as activators in some specific cases [17].
All the mentioned epigenetic pathways can interact. For instance, there is evidence of an interaction between HDAC
and PRC1 (and possibly PRC2) [18]. Notwithstanding their importance, the number of experimentally validated
miRs involved in regulatory circuitries with the above-mentioned epi-Rs, from here on referred to as epi-miRs, is
still very small, their identification episodic, and no attempt was performed up to now for a systematic search. The
main goal of this paper is to fill this gap. We propose a simple protocol to identify candidate epi-miRs and study
their mechanism of action combining gene expression datasets coming from experiments of overexpression of a
given miR and data of knockdown, knockout, drug-mediated downregulation or chromatin immunoprecipitation
(ChIP) experiments of a given epi-R (from here on referred to as epi-R ablation).
Moreover, our procedure can also be used to identify candidate epigenetic interactors of a given miR of interest
and as an example we studied the case of miR-214, a prometastatic miR [19,20] involved in the coordination of
melanoma tumor cell migration, invasion, adhesion to extracellular matrices, transendothelial migration and survival
to anoikis in vitro, as well as extravasation from blood vessels and metastasis formation in vivo [19]. miR-214 acts
through the simultaneous coordination of a network including over 70 protein-coding genes and the antimetastatic
small noncoding RNA, miR-148b [20]. In the present work, we experimentally proved that the EZH2, the main
component of the PRC2, is an interactor of miR-214, involved, at least partially, in the activation of miR-214
downstream players: ITGA5, ALCAM and the small noncoding RNA, miR-148b. Due to the importance of EZH2
as a crucial epi-R involved in the initiation and advancement of melanoma [21], the described miR-214-EZH2 axis
could be of potential interest to understand tumor progression.
Methods
GSEA gene sets
Gene sets were downloaded from the MSigDB database (v5.2 updated October 2016) [22,23], which contains gene
sets collected from various sources, from on-line pathway databases to PubMed publications. We selected a panel
of gene sets broadly related to epigenetic pathways as discussed in the main text. We chose, when possible, multiple
sets for a specific component, spanning over different tissues or experimental conditions. We ended up with a
panel of 43 sets, summarized in Supplementary File 1. These sets can be divided into two main classes: results of
ChIP experiments, whose entries allow to directly identify putative targets of the selected factor; results of gene
expression experiments after knockdown, knockout or drug-mediated downregulation a particular epi-R. In this
case, we downloaded separately both the upregulated and the downregulated genes. These allow us to fix also the
sign and in some cases the direction of the regulatory interactions we found.
miR transfection experiment datasets
Fourteen series of miR transfection experiments on five different platforms by Seki et al. [24–38], for a total of 157
gene expression datasets involving 59 miRs transfected in different human cancer cell lines were downloaded from
GEO. Gene expression data were obtained using Agilent whole-genome microarrays. An experiment series from
Misiewicz-Krzeminska et al. [39], containing data from miR-214 expression in H929 myeloma cell lines was also
downloaded to support our experimental data. The data were LOWESS normalized and background subtracted
from log10 of processed Red signal/processed Green signal by the author through Agilent software (Supplementary
File 2). Some of the gene names annotated to the probes were obsolete and we updated them, exploiting the
bioconductoR (Bioconductor 3.2, R 3.2.3) package biomaRt (v. 2.34.2) [40]. Then, we selected the probes with
the highest fold change across each platform, we selected a unique set of genes conform to all the experiments
considered to use as universe gene set (containing 17,025 genes) and applied an arbitrary, the literature-approved,
threshold of t = 0.5 on the log10 (fold change) of the expression data to select the up-/downregulated genes for
each experiment in the Seki panel and in the GSE35948-miR-214 panel.
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miRTarBase targets
The miRTarBase database [41] was used to identify putative targets broadly related to the epigenetic pathways we
were interested in. We differentiated among weak (validated by CLIP-seq) or strong (validated using reporter assays
or western blots) miR-target interactions by the database annotation.
TargetScan analysis
TargetScan (http://www.targetscan.org/vert 72/) [42] was used to compare our results with those expected by a
canonical miR-target direct-repressive interaction. We downloaded the files for conserved and not conserved miR-
families and sites of interaction (TargetScan release 7.2, March 2018) and we computed the number of predicted
targets with no regard for the conservation or the score given to a specific site. To avoid repetitions, we performed the
statistical analysis only on those miRs that resulted miR or candidate epi-miRs in all the transfection experiments.
Reagents & antibodies
Pre-miR miRNA Precursor Molecules Negative Control 1, miRNA precursors hsa-miR-214 (PM12124; Ambion,
TX, USA). TaqMan miRNA assays for miRNA detection: hsa-miR-148b (000471) and U6 snRNA (001973)
(Applied Biosystems, CA, USA). siRNAs: siEZH2 (Hs-EZH2- FlexiTube siRNA SI02665166) and All Stars
Negative Control siRNA were purchased from Qiagen (CA, USA). Primary antibodies: anti-actin pAb I-19
and anti-GAPDH pAb V-18 were from Santa Cruz Biotechnology (TX, USA); anti-ITGA5 pAb RM10 was
kindly provided by G Tarone (University of Torino, Torino, Italy); anti-EZH2 mAb #612666 (BD, Transduction
Laboratories, CA, USA); anti-CD166/ALCAM mAb MOG/07 (Novocastra Laboratories, Newcastle Upon Tyne,
UK). Secondary antibodies: goat antimouse and goat antirabbit HRP-conjugated IgG were from Santa Cruz
Biotechnology. All antibodies were used at the producer’s suggested concentrations. Real-Time assays: QuantiTect
Primer Assay (200) Hs-GAPDH-1-SG QuantiTect Primer Assay QT00079247, QuantiTect Primer Assay (200)
Hs-ALCAM-1-SG QuantiTect Primer Assay QT00026824; QuantiTect Primer Assay (200) Hs-ITGA5-1- SG
QuantiTect Primer Assay QT00080871 (Qiagen, CA, USA).
Cell culture
MA-2 cells were provided by R.O. Hynes (Massachusetts Institute of Technology, MA, USA) and maintained as
described previously [19,20].
Transient transfections of pre-miRs & siRNAs
To obtain transient pre-miR or siRNA expression, cells were transfected using RNAiFect (Qiagen, CA, USA)
reagent, 75 nM pre-miR and 170 nM siRNA, as described in [19].
RNA isolation & quantitative Reverse Transcription (qRT)-PCR for miRNA or mRNA Detection
Total RNA was isolated from cells using TRIzol Reagent (Invitrogen Life Technologies, CA, USA) according to
manufacturers’ protocol. qRT-PCRs were performed as described in [19].
Gene expression profiling
Protein-coding expression profiling was carried out using the Whole Human Genome Oligo Microarray (41,000,
60-mer oligonucleotide probes) from Agilent Technologies. Total RNA (800 ng) was labeled by the Agilent
One-Color Microarray-Based Gene Expression protocol, according to the manufacturer’s instructions. Slides were
scanned on an Agilent microarray scanner. Analysis was performed as described in [43]. Gene expression data
are available in the U.S. Center for Biotechnology Information Gene Expression Omnibus (GEO) database
(GSE124965).
Protein preparation & western blotting
Total protein preparation and western blot analysis were performed as described in [19].
Statistical analyses for biological experiments
Data are presented as mean standard deviation (SD) or as mean standard error of the mean (SEM), as indicated,
and two-tailed Student’s t-test was used for comparison, with, p < 0.05; p < 0.01; p < 0.001 considered to be
statistically significant. - indicates a non-statistically-significant p-value.
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Results
Bioinformatics workflow for the identification of candidate epi-miRs
The interplay of miRs and epi-Rs in regulatory networks can lead to extremely complex patterns of gene expression.
However, it should be possible to infer the most likely regulatory circuitries underlying specific expression patterns,
at least in simple cases. In general, the interaction between a miR and a global epi-R could lead to an epigenetic
‘amplification’ of the miR action that may explain the episodic empirical observation of a large number of genes
varying their expression in miR transfection experiments. We propose a simple, but powerful method to test if this
amplification is really the signature of the action of an epigenetic amplification starting from gene expression data
of miR overexpression experiments together with data obtained following epi-R ablation. The rationale behind
our approach is that, since most of considered epigenetic pathways are repressors of gene expression, if they are
controlled (i.e., downregulated) by a miR, then all the genes targeted by the epigenetic machinery should be
upregulated when the miR is overexpressed. All cases in which no significant intersection was observed between the
miR and the epi-R regulated genes (see Figure 1A) were not further considered in our analysis because we assumed
that the two players did not act cooperatively. Regulatory circuitries were considered when we found significant
intersections: between the downregulated genes following miR overexpression and the upregulated genes in epi-R
ablation experiments (Figure 1B); between the downregulated genes following miR overexpression and the epi-R
ablation (Figure 1C); between the upregulated genes observed in both conditions (miR overexpression and epi-R
ablation, Figure 1D); when the intersections described in Figure 1C and D were identified for the same miR in the
same epigenetic pathway (Figure 1E). Clearly, this is a simplified view. Undirect interactions and more complex
regulatory networks and cascades can, in principle, lead to similar expression patterns. Therefore, the regulatory
circuits in Figure 1 should be seen as the most basic interactions between miR and epi-miR compatible with
the experimental expression patterns. For example, cases in which several genes are both upregulated after miR
overexpression and downregulated after epi-R ablation cannot be explained by these simple circuitries and require
additional regulatory players.
More in details, the analysis was organized in three steps as depicted in Figure 2. First, we identified a panel
of gene sets which could be considered strongly associated to epigenetic regulation. To this end, we selected the
gene sets available from the gene set enrichment analysis (GSEA) database (software.broadinstitute.org/gsea/) [22,23]
coming from epi-R ablation experiments. The main assumption in our protocol is that the epigenetic regulation is
so strong and widespread that several of the target genes do not depend on the cell lines used in the experiment and
can be used as a benchmark of the activation of the epigenetic pathway of interest. We chose gene sets associated
to each of the epigenetic pathways discussed above, identifying 43 gene sets (reported in Supplementary File 1).
The representation of the different epi-Rs in the identified datasets is summarized in Figure 3A. Briefly, 20 of them
are specifically devoted to the PRC2 and contained both manually curated lists and experiments looking for the
histone mark H3K27me3 associated to the PRC2 activity; while 23 were devoted to the other three epigenetic
pathways discussed above. The number of genes contained in the sets ranges from 11 to more than 900, the
majority of them (around 60%) contains up to 150 genes. Some of the sets have a strong overlap in their gene
content and we use them as a cross-check of the procedure. As second step, we used the above panel to evaluate for
any given miR transfection experiment the probability of the involvement of the miR in one (or more) epigenetic
pathways under study. To this end, we evaluated the intersection between each of the 43 gene sets and the sets
of genes upregulated and downregulated in the transfection experiments. The significance of this intersection was
assessed by a hypergeometric test corrected for multiple testing using the Benjamini–Hochberg procedure in order
to have a well-defined false discovery rate (FDR). We set a threshold of 0.001 for the FDR. All the entries below
this threshold represent candidate associations between a miR and an epigenetic pathway, which we prioritize for
further analysis. Finally, in the third step, we classified the significant intersections in the different type of circuitries
described in Figure 1. This could be accomplished, thanks to the fact that some of the gene sets correspond to
Chip-seq experiments of epigenetic factors and that in other cases we have both the set of genes upregulated and
downregulated when silencing crucial components of a given epigenetic machinery.
Identification of candidate epi-miRs
In order to test our procedure, 14 experiment series (Supplementary File 2) for a total of 157 miR transfection
experiments (Supplementary File 3) involving 59 different miRs on 26 different cell lines were downloaded
from Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/). This particular panel of
transfections was chosen among the hundreds of miR transfection experiments available in the GEO database,
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Figure 1. Schematic view of considered circuitries between miRNAs and epigenetic regulators. miR overexpression
or epi-R ablation or chromatin immunoprecipitation experiments were used to identify the pattern of miR and epi-R
interactions. The putative circuitries between miR and epi-R are depicted. In (A), miR and epi-R do not interact and
regulate distinct sets of genes; in (B), they repress an overlapping set of genes; in (C), the epi-R represses the miR; in
(D), the miR represses the epi-R; in (E), both (C) and (D) situations are present for the same miR and the same
epigenetic pathway. The up arrows indicate the sets of genes upregulated in the depicted experiments, while the
down arrows indicate the sets of downregulated genes. Cases in which the genes were upregulated after miR
overexpression and downregulated after epi-R ablation were not took into consideration because it was not possible
to group them under a single common theoretical circuit.
epi-R: Epigenetic regulator; miR: miRNA.
because they are characterized by a high level of homogeneity and consistency both of the experimental protocol
and the data curation. Thirty-four out of 59 miRs resulted as candidate epi-miRs: 19 are known as epi-miRs, while
15 are identified as new, a pie chart showing the percentage of the different classes of miR/epi-miR is shown in
Figure 3B. The results of the best intersections obtained for each candidate epi-miR and the associated epigenetic
pathway are summarized in Table 1, where in the second column the association of each miR to the putative
targeted epigenetic pathway is shown. In third, fourth, fifth and sixth columns, the potential loops between the
candidate miR and epi-R belonging to the categories described in Figure 1 are indicated. Finally, in the last column,
the results obtained using the miRTarBase database of experimentally validated miR-target interactions [41] are
indicated (Supplementary File 4). Pathways displaying very strong signatures (FDR < 10 × 10-8) are reported in
bold face (complete list of intersections in Supplementary File 5). More than half (34) of the 59 miRs transfected
in the analyzed panel of experiments turned out to be candidate epi-miRs. Notice, however, that this observation
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Figure 2. Schematic pipeline of our analysis. Each miRNA (miR) transfection experiment gene set was divided in up-/downregulated
gene sets, and for each of them was computed the intersection with the mSigDb gene sets. The significance of these intersections has
been evaluated through a hypergeometric test and corrected for multiple testing by the Benjamini–Hochberg procedure. All of the miRs
involved in intersections with false discovery rate lower than 0.001 were selected as candidate experimentally validated miR. Results were
further refined through gene set enrichment analysis, Database for Annotation, Visualization and Integrated Discovery, miRTarBase or
TargetScan analysis, and each miR–epigenetic regulator interaction was labeled on a specific theoretical circuit based on the sign of the
miR gene set and the type of epigenetic gene set involved in the intersection.
DAVID: Database for annotation, visualization and integrated discovery; epi-miR: Epigenetic miRNA; GSEA: Gene set enrichment analysis.
can be influenced by the fact that most of the miRs included in the panel are known to be involved in cancer or
in differentiation processes and thus more likely to be involved in epigenetic pathways. In most of the cases (182
intersections corresponding to 55 different transfection experiments), we found very low FDR for the intersections
of the upregulated genes with the GSEA sets, which could be compatible with a direct interaction of the miR
with an epi-R. Interestingly, we also found quite a few examples (93 intersections corresponding to 38 different
transfection experiments) of significant intersections for the downregulated genes. In a few cases, when transfection
experiments of the same miR in different cell lines were available, we found that the same miR may act as an
epi-miR in one particular cell line and show no epigenetic effect in the other cell lines.
The results showed a few clear correlations between the different epigenetic pathways analyzed. In general, for
several miRs, we found signatures for more than one epigenetic pathway (23/34 epi-miRs, see Table 1). In some
cases, it is difficult to disentangle if these are due to a direct interaction of the miR with the epi-R or are triggered
by the disregulation of other epigenetic pathways.
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Figure 3. Candidate experimentally validated miRNAs show a large number of differentially expressed genes. (A) Percentage
distribution of the mSigDb gene sets used among the epigenetic pathway taken into consideration. (B) Percentage distribution of
candidate or not-candidate epi-miRs as resulted by our analysis. For those that resulted to be candidate epi-miRs, the percentages of new
and known epi-miRs are reported. (C) Scatter plot showing the distribution of the difference among up- and downregulated genes
(upregulated genes–downregulated genes) versus the total number of differentially expressed genes for all analyzed transfection
experiments on the basis of the significance of their intersection with the gene set enrichment analysis sets. Each symbol represents one
of the transfection experiments listed in Supplementary File 3. The epi-miR and miR identified by the gene set enrichment analysis
intersection analysis are shown in red color gradation as indicated in the false discovery rate color bar. (D) Box plots representing the total
number of differentially expressed genes for the indicated (n) number of experiments, discriminating between those where the miRs
turned out to behave as epi-miRs (red, left) and those where they acted as regular miRs (blue, right). In (C), false discovery rate was
obtained using a Benjamini–Hochberg procedure. In (D), significance was assessed using a Mann–Whitney U two tailed test,
****p-value <0.0001; - a nonstatistically significant p-value.
epi-miR: Experimentally validated miRNA.
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Table 1. List of candidate epigenetic miRNAs.
B C D E
miR Associated pathway
miR epi-R epi-RmiR miR epi-R
epi-RmiR
MirTarBase
miR-1 PRC1, PRC2, HDAC PRC2, HDAC PRC2 PRC2 PRC2 HDAC
miR-133a PRC1, PRC2, HDAC PRC2 PRC2, HDAC PRC1, PRC2, HDAC PRC2, HDAC
miR-138 PRC1, DNMT, PRC2,
HDAC
PRC1, DNMT, PRC2,
HDAC
miR-141 PRC2 PRC2
miR-144 PRC2, HDAC PRC2, HDAC PRC2
miR-145 PRC2, HDAC, PRC1,
DNMT
PRC2 PRC2 PRC2, PRC1, DNMT,
HDAC
PRC2
miR-145-5p PRC2, PRC1 PRC1, PRC2
miR-149 PRC1, PRC2, HDAC HDAC PRC1, PRC2
miR-150 PRC2 PRC2
miR-183 PRC2, HDAC PRC2 PRC2, HDAC PRC2 PRC2
miR-185-5p DNMT DNMT DNMT
miR-199 PRC2 PRC2
miR-200a PRC2 PRC2 PRC2
miR-205 PRC2 PRC2 PRC2 PRC2 PRC2
miR-210 PRC1, PRC2, HDAC PRC1, PRC2, HDAC
miR-218 PRC2, DNMT, PRC1 PRC2 PRC2 PRC1, PRC2 PRC2
miR-221 HDAC, PRC2, PRC1 PRC2, HDAC PRC2 PRC2 PRC2
miR-222 PRC2, PRC1, HDAC PRC2 HDAC PRC2
miR-223 PRC1, PRC2, HDAC HDAC PRC2
miR-223-5p PRC2 PRC2 PRC2
miR-224 PRC2 PRC2 PRC2
miR-23b HDAC, PRC2, PRC1 PRC2 HDAC, PRC1 PRC2, HDAC HDAC
miR-24 PRC2, HDAC, PRC1 PRC2 PRC2, HDAC PRC1, PRC2 PRC2 PRC1, HDAC
miR-29a PRC1, PRC2 PRC1, PRC2
miR-27b PRC2 PRC2
miR-30a-5p PRC1, PRC2 PRC2, PRC1 PRC2
miR-31 DNMT, PRC2, HDAC PRC2, HDAC
miR-375 PRC2, PRC1, HDAC PRC2 HDAC PRC1, PRC2, HDAC HDAC
miR-451 PRC2, PRC1 PRC1, PRC2
miR-504 PRC2 PRC2
miR-517a PRC2, HDAC PRC2, HDAC
miR-874 PRC2 PRC2
miR-96 PRC2, PRC1, HDAC PRC2 PRC1, PRC2, HDAC
miR-99a PRC2, HDAC PRC2 PRC2, HDAC PRC2 PRC2
For each candidate experimentally validated miR (epi-miR), we list in the second column the pathways in which they are involved (associated pathways): in some cases, a significant
intersection was found between the genes upregulated after miR overexpression and downregulated after epigenetic regulator ablation. These cases were not further analyzed because it
was not possible to group them under a single common theoretical circuit. The other cases are listed in columns third, fourth, fifth and sixth, where the involvement of the epi-miR in the
different loops described in Figure 1 is indicated in the headings of the table. The bold face in these columns refers to the pathways associated with very strong signatures (false discovery
rate 10× 10-8). Finally, in the last column, the results of miRTarBase analysis are reported: the italic face in this column indicates the functional targets supported by strong experimental
evidence, based on the indications of miRTarBase.
epi-R: Epigenetic regulator; miR: miRNA.
We observed that transfection experiments for our candidate epi-miRs are characterized by a large number of
regulated genes (Figure 3C–D) with a slight tendency toward upregulated versus downregulated genes (Figure 3C
& Supplementary Figure 6A), a signature compatible with a widespread action of epi-Rs. As shown by the box-plot
analysis, the total number of differentially expressed genes resulted significantly higher for the experiments where
the miR turned out to be a candidate epi-miR compared with experiments where the miR was not identified as
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a candidate epi-miR (Figure 3D). The categorical scatter plot (Figure 4A) shows the amount of the differentially
expressed genes in the different transfection experiments for each candidate epi-miR. Histogram in Figure 4B
shows that the difference between the distribution of the average of the total number of differentially expressed
genes for each transfection experiment and each analyzed miR is significantly higher in miRs acting as epi-miRs as
assessed by Mann–Whitney U two-tailed test. Moreover, a TargetScan analysis of predicted targets of the candidate
epi-miRs did not show a significant difference in number compared with the predicted target genes of the other
miRs (Supplementary Figure 6B).
We describe below a few instances of our results, which we chose both for the relevance of the pathways in which
the candidate epi-miRs are involved and because they represent paradigmatic examples of the different combination
of entries that we found in our analysis.
Examples of candidate epi-miRs identified with our pipeline
miR-31
In the panel of the analyzed transfection experiments, miR-31, a typical miR deregulated in cancer, was present
in a single transfection experiment in the human highly metastatic prostate cancer cell line, PC3. Looking at the
intersections with our gene sets, four entries were observed (FDR <0.001, see Supplementary File 7). All of them
were for the set of genes upregulated after transfection (NUYTTEN EZH2 TARGETS UP, SENESE HDAC1
TARGETS UP, SEN ESE HDAC3 TARGETS UP and GSE27434WT VS DNMT1 KO TREG DN). Three
sets contained genes upregulated after knockout of EZH2, HDAC1 and HDAC3, suggesting a direct inhibition
of these three genes by miR-31 or more generally on the corresponding epigenetic machinery as shown in the third
column of Table 1.
miR-205
As for miR-31, also miR-205 was not previously known as an epi-miR. For miR-205, three experiments on
three prostate cancer cell lines (PC3, DU145 and C4-2) were present in our panel. A larger number (seven)
of significant intersections with our gene sets both for the upregulated and downregulated genes was observed
with very low FDR (Supplementary File 7). Interestingly, for one of the EZH2-related files, the FDRs are re-
ally low (down to 10 × 10-47) and genes show consistent signatures in the upregulated and downregulated
sets. More precisely, the upregulated genes are the same found upregulated after knockout of EZH2 (NUYT-
TEN EZH2 TARGETS UP, FDR = 10 × 10-22) and downregulated those which are downregulated after knockout
of EZH2 (NUYTTEN EZH2 TARGETS DN, FDR = 10 × 10-47).
miR-138
Differently from the previously described miRs, miR-138 is a well-known epi-miR [7], in this case only one
transfection experiment in the A498 kidney carcinoma cell line was present in the considered datasets. Eight
intersections (FDR <0.001) were observed and all of them in the set of genes downregulated after transfection.
Noteworthy, in all these cases, the gene sets are incoherent with respect to the expected epi-miR interaction. For
instance, we found among the downregulated genes a large number (FDR = 10 × 10-19) of genes upregulated after
knockout of EZH2. This means that these genes are simultaneously targets of miR-138 and EZH2. We report as
an example the intersection corresponding to the file NUYTTEN EZH2 TARGETS UP mentioned above. This
intersection is composed by 95 genes which are listed in the Supplementary File 7 (FDR = 10 × 10-19). Performing a
Gene Ontology analysis (DAVID tool online https://david.ncif crf.gov/home.jsp) [44,45], entries related to immune
response with a low Bonferroni corrected p-value of 10 × 10-8 were observed (Figure 5A), underlining that a large
portion of these genes is activated only following a perturbation of the immune system and should be otherwise
kept silenced.
miR-145
The well-known epi-miR, miR-145, is the miR with the largest number of available transfection experiments, in
some cases on the same cell lines. miR-145 is simultaneously involved in several different epigenetic pathways (see
Table 1). In particular, we found strong evidence of a direct involvement in the regulation of the two Polycomb
pathways, PRC1 and PRC2, and of the DNMT machinery. Most relevantly, the same pathway is regulated in
several different cell lines, for instance, PRC2 is downregulated not only in LNCap but also in PC3 and DU145
prostate cancer cell lines. Interestingly, a direct inspection shows that the effect of the downregulation of PRC2 is
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very similar in the three cell lines. In other words, there is a large overlap among the genes that are upregulated in
the three experiments (notwithstanding the difference in cell lines) and these upregulated genes are exactly those
which are targeted by PRC2 (data not shown).
miR-1
A very interesting pattern was found in the case of the well-known epi-miR,miR-1 [7], which appeared in ten entries
of our panel of transfection experiments, but only for two of them, corresponding to the PC3 (prostate cancer)
and EBC-1 (lung cancer) cell lines, the intersection had a FDR <0.001. In particular, in lung cancer EBC-1 cells,
there was a strong indication supporting a direct downregulation of PRC2. What is relevant is that this signature
appears in a consistent way both in the set of the upregulated and downregulated genes (see data in Supplementary
File 7). We found a large overlap (FDR = 10 × 10-73) between the set of genes downregulated after transfection
of the miR and the genes downregulated after knockout of EZH2 and, simultaneously, a large overlap (FDR = 10
× 10-16) of the genes upregulated after transfection with those upregulated after knockout of EZH2. The set of
common upregulated genes shows a strong overlap with the same GO categories mentioned above on immune
response (Figure 5B), while a GO analysis of the set of downregulated genes shows that most of these genes are
associated to cell cycle (Figure 5C).
GO categories for miR-31, miR-145 and miR-205 are shown in Supplementary Figure 8.
miR-214 modulates multiple genes in melanoma cells
The procedure we propose can be used given a miR of interest, to identify its candidate epigenetic interactors. Due
to the relevance of miR-214 in tumor progression, we are continuously investigating unknown mechanisms through
which miR-214 could coordinate tumor metastatization. In the attempt to identify new genes directly or indirectly
modulated by miR-214, MA-2 [19] aggressive melanoma cells were transiently transfected with a precursor for
miR-214 (pre-miR-214) or negative controls (precontrol). RNA was extracted 72 h following transient transfection
and miR-214 expression levels verified by real-time PCR (data not shown). RNA was used to perform whole human
genome gene expression analysis (GSE124965). A total of 493 differentially expressed genes (342 upregulated; 88
downregulated) were found, considering a 14.2% FDR. Surprisingly, 342/493 of the differentially expressed genes
resulted to be upregulated, suggesting a possible indirect regulation of these genes by miR-214 via a potential
crosstalk with an epi-R. Similar observation came from the analysis of another miR-214 dataset (GSE35948) [39].
The first hypothesis we made was that miR-214 could influence the expression of this huge amount of genes via
an epigenetic mechanism. For this reason, the list of the differentially expressed genes was subjected to the analysis
described above to identify candidate epigenetic interactors of miR-214. The lists of the differentially expressed
genes used for the analysis is available in Supplementary File 9. The heatmaps for both datasets are shown in
Figure 6A and B, where it is qualitatively appreciable the increased number of upregulated genes compared with
downregulated ones following miR-214 overexpression.
Eight GSEA sets were identified, across up- and downregulated gene sets using both our (GSE124965) and
GSE35948 [39] datasets (Supplementary File 10), showing evidence of a direct regulation of the miR on the
considered epigenetic pathways. Five of them correspond to the PRC2 pathway and two correspond to HDACs.
In particular, the PRC2 sets are related to the silencing of the enhancer of zeste 2 polycomb-repressive complex 2
subunit (EZH2) and to the silencing of the EZH2 interactor NIPP1 (Supplementary File 10), suggesting EZH2
as the candidate gene directly targeted by miR-214 and responsible for the vast upregulation observed in the
experimental dataset. GSEA analysis of the genes belonging to the best PRC2 intersection, described above, shows
a significant enrichment with sets related to epithelial-to-mesenchymal transition and TGFb pathway in agreement
with the prometastatic role of miR-214 (Figure 7).
miR-214 downregulates EZH2
In order to prove that miR-214 targets EZH2 gene in a melanoma cell context, miR-214 was overexpressed in MA-2
melanoma cells and EZH2 protein expression levels analyzed. As shown in Figure 8A, miR-214 overexpression leads
to a 60% reduction of EZH2 protein levels. To verify if EZH2 silencing could phenocopy miR-214 overexpression
effects on the activation of miR-214-dependent downstream pathway, ITGA5 and ALCAM, and miR-148b
expression levels were analyzed. As shown in Figure 8B and C, EZH2 silencing (60%) was able to induce an
upregulation of ALCAM (32%) and ITGA5 (60%) expression, thus phenocopying the effects observed following
miR-214 overexpression [20]. Interestingly, ALCAM and ITGA5 were not consistently modulated at the mRNA
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level. In order to asses if EZH2 could be partially involved in miR-214-mediated miR-148b dowmmodulation,
we tested miR-148b expression levels following EZH2 silencing and as shown in Figure 8D. EZH2 silencing was
able to decrease miR-148b expression, suggesting a partial contribution of EZH2 in miR-214-mediated control
of miR-148b. All these data suggest that miR-214 could potentially act, at least partially, through an epigenetic
mechanism together with the classical mechanism of action in controlling metastatization.
Discussion
We selected a panel of gene sets which can be considered bona-fide targets of the above-discussed main epigenetic
pathways and intersected them with the set of genes, respectively, upregulated or downregulated in a series of
gene expression datasets coming from publicly available transfection experiments of various miRs. Intuitively, a
large intersection could be considered as a signature of an epigenetic amplification. The p-value of the intersection
was assessed using the hypergeometric distribution corrected for multiple testing. Our analysis shows that the
interaction between miRs and epi-Rs is widespread. Epi-miRs are typically involved in differentiation processes
and are likely to play an important role in cancer, where accumulating evidence shows that epigenetic alterations
exert pivotal roles in tumor progression. When transfection experiments in more than one cell line were available,
we found that the epigenetic role of miRs is strongly tissue dependent, in fact, the same miR can strongly interact
with an epi-R in a particular tissue or cancer cell line and may have no effect at all in another cell line.
An interesting feature of most of the known epi-miRs is that they are typically involved in complex double
inhibitory feedback loops with their epigenetic targets. It has been shown that this circuit is perfectly suited for
tissue differentiation and more generally to choose among different cell fates and keep memory of this choice [12].
The nature of the two partners (miR and epi-R) of the feedback loop ensures an optimal resistance to stochastic
fluctuations and avoids erroneous switching of the loop [12]. Several of the identified epi-miRs follow this same
pattern, but due to the nature of the data used in our analysis we cannot close the circuits for all the identified
candidate epi-miR except for the ones presented in Table 1, column sixth. We discuss here a few examples of
epi-miRs which are presented in the Results section.
MiR-31 is an important regulator of tumorigenesis where it can function either as an oncomiR or as a tumor-
suppressive miR. This miR was not previously known as an epi-miR and there are no entries in the miRTarBase.
miR-31 has been recently shown to be a transcriptional target of EZH2 [46,47]. Together with our findings, this
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observation closes a perfect toggle switch (see Figure 1E) which, as mentioned above, is a typical signature of
epi-miRs. In agreement with this switch-like behavior, it was shown that in colorectal cancer cell lines [46], there is
a systematic inverse association between EZH2 and miR-31 expression levels.
Remarkably enough, it has been recently shown that a similar feedback loop is also present with the other
epigenetic pathways. Indeed, it was shown that HDAC inhibitors enhance the expression level of miR-31 [48].
Moreover, also the association between the HDAC and the PRC2 pathways that we observed in our data is
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confirmed in the literature, in fact, it has been shown recently that in some classes of tumors the inhibition of
miR-31 requires the joint action of EZH2 and HDAC [49].
As for the previous miR, also miR-205 may act either as a tumor suppressor through inhibiting proliferation
and invasion, or as an oncogene through facilitating tumor initiation and proliferation, depending on the specific
tumor context and target genes. miR-205 belongs to the miR-200 family and is involved in the regulation of EMT.
As for miR-31 also miR-205 was not previously reported as an epi-miR. Also in this case, there is evidence of a
double inhibitory feedback loop with EZH2 [50].
Differently from the previously described miRs, miR-138 is a well-known epi-miR, it is involved in a double-
negative feedback loop both with SIRT1 [51], which is a component of the HDAC pathway and with EZH2 [52,53].
These circuits are prototypical examples of epigenetic feedback loops [12]. What is interesting is that in all these
cases, the gene sets are incoherent with respect to the expected epi-miR interaction. This means that these genes
are simultaneously targets of miR-138 and EZH2. The type of circuit that we found is depicted in Figure 1B.
This circuit is very interesting because it ensures that the target genes are always silenced, independently from the
orientation of the regulatory switch. What is more important, due to the incoherent nature of the circuit, their
expression levels are not only low but are stable against fluctuations. These target genes are likely to be important
regulator themselves, which in physiological conditions must be kept under control while are disregulated during
cancer progression.
miR-145 is a known tumor suppressor that impacts on tumor cell growth and invasiveness, plays important roles
in the differentiation of stem cells and vascular smooth muscle cells and regulates the expression of core stemness-
associated factors, such as OCT4, SOX2 and KLF4 [54]. It is interesting to notice that also for this miR, there are
strong indications suggesting the presence of a double inhibitory feedback loop with DNMT [55]. This agrees with
independent observations: for instance, it was shown to be suppressed by hypermethylation in tumors [56] and it is
downregulated in lung adenocarcinoma tissues in association with increased DNA methylation [57]. The DNMT
pathway is indeed one of the pathways that we found as direct targets of miR-145 in our analysis (see Table 1).
Finally, a very interesting pattern is found in the case of the well-known miR-7 [7], for which GO categories show
an enrichment in immune response and cell cycle inhibition categories and our findings suggest that it exerts these
functions by targeting the PRC2 pathway.
Our pipeline can be used to identify putative epigenetic interactors of any given miR. The prometastatic miR-214
has been used as an example of the potentiality of our methods. Based both on a dataset from our transfection
experiments and from a publicly available dataset, we identified EZH2 as an epigenetic interactor of miR-214. We
demonstrated that miR-214 regulates EZH2 in melanoma cells and EZH2 is, in turn, at least partially responsible
of the downstream pathway activated by miR-214 involving ALCAM, ITGA5 and miR-148b. These results were in
agreement with previous data regarding miR-214 regulation of EZH2 during muscle differentiation [58]. Moreover,
the GSEA analysis performed for the best intersection of miR-214-regulated genes with the selected GSEA sets
used in our analysis shows an enrichment in EMT and TGF-β-related genes, perfectly in agreement with the
prometastatic role of miR-214 during tumor progression. The identification of miR-214 as an epi-miR in a tumor
cell context highlights new layers of regulation of this miR in the control of tumor progression.
Conclusion
Some of our candidate epi-miRs agree with already published findings, and represent a positive test of our procedure,
but some of them are new and represent one of the main results of this paper. Altogether our findings point to
a much stronger role of epi-miR in the regulatory network of higher eukaryotes and more generally to a strong
interplay between the post-transcriptional and the epigenetic layers of regulation in shaping the differentiation
process of complex tissues.
Future perspective
The alteration of epigenetic mechanisms can cause several serious pathologies, including cancers, cardiovascular,
metabolic, neurodegenerative disorders as well as inherited syndromes. Recently, growing evidence demonstrates
that miRs influence epigenetic mechanisms, via regulation of epigenetic factors, and at the same time, many miRs are
under a strict epigenetic control. Given the importance and complexity of this interplay, the epigenetic mechanisms
can be only understood considering the regulatory circuitries composed of miRs and epigenetic regulators. Our work
contributes to better elucidate and to identify new player involved in these complex regulatory circuits. Although
the presented pipeline was applied on gene sets from tumor origin, it could be applied to different pathologies
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beside cancers. Notably, our approach could be used in the future to go more in details in this regulations to
verify how much these circuitries are similar among cells of the same tissue of origin or cells derived from the
same kind of tumors as well as to unravel the pathological implications of new epimiR. Potentially, the level of
resolution could also be increased in order to discriminate among the different members of the epigenetic regulator
family involved in the circuits. Moreover, an enhanced resolution will also help to better elucidate and dissect the
molecular mechanism. Due to the relevance of these regulatory circuitries in the future, many more studies and
new methodologies will be developed to shed light on this new level of regulation.
Summary points
• miRNAs (miRs) are small noncoding RNAs able to post-transcriptionally regulate gene expression.
• miRs can cross-talk with other regulatory genes such as the epigenetic factors, amplifying their regulatory
potential.
• miRs-regulating epigenetic factors are denoted as epi-miRNAs (epi-miRs).
• Starting from pre-existing miR transfection experiments, we identified 34 candidate epi-miRs: 19 of them are
known as epi-miRs, while 15 are new.
• We found that the same miR may act as an epi-miR in one particular cell line and show no epigenetic effect in the
other cell lines.
• Using an in-house generated gene expression dataset, we experimentally proved that, a component of the
polycomb-repressive complex 2, histone methyltransferase enhancer of zeste homolog 2 (EZH2), is an interactor
of miR-214, a well-known prometastatic miR in melanoma and breast cancer.
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